Use of Heberferon for the Treatment of Nevoid Basal-Cell Carcinoma Syndrome (NBCCS) (GORLIN SYNDROME)

December 11, 2018by CubaHeal Research0

What is Nevoid Basal Cell Carcinoma Syndrome (NBCCS)?

Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is a rare genetic disease that predisposes patients to develop multiple basal cell carcinomas (BCCs), mandibular cysts, and bone abnormalities.

Causes and Risk Factors:
  • Genetic mutation: NBCCS is linked to mutations in the PTCH1 gene, which is part of the Hedgehog signaling pathway, crucial for cell development.
  • UV exposure: Patients with NBCCS are extremely sensitive to ultraviolet radiation, which accelerates the appearance of skin lesions.

In Latin America, where sun exposure is high and prevention programs are limited, this syndrome represents a significant challenge in terms of diagnosis and management.

Heberferon
HeberFERON: Cuban Innovation for the NBCCS

HeberFERON, developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba, is an innovative therapy specifically designed to treat basal cell carcinoma, including in cases associated with NBCCS. This drug combines interferons alpha-2b and gamma, achieving synergistic effects to control tumor growth.

Mechanism of Action:
  • Reduced tumor proliferation: HeberFERON acts directly on cancer cells, inhibiting their growth.
  • Decreased inflammation: Promotes an immune response that helps prevent tumor recurrence.

HeberFERON is particularly effective at treating injuries in sensitive areas, such as the face, where surgical options can prove disfiguring.

Benefits of HeberFERON vs. Conventional Treatments

HeberFERON offers a safe and effective alternative to traditional treatments for basal cell carcinoma, such as surgery and radiation therapy.

  1. Mohs Micrographic Surgery:
  • Advantages: High precision to eliminate tumors.
  • Cons: Invasive and can leave visible scars, especially in delicate areas such as the face.

2. Radiation therapy:

  • Pros: Useful in advanced cases.
  • Cons: Risk of damage to healthy tissues and possible long-term side effects.
3. HeberFERON:
  • Advantages:
  1. In the invasive.
  2. Preserves aesthetics in visible areas.
  3. It significantly reduces recurrence rates.
  • Cons: Requires a strictly supervised enforcement protocol.

Clinical studies have shown that HeberFERON can reduce the size of lesions by 75-100% in cases of NBCCS, with minimal side effects compared to traditional treatments.

Success Stories and Clinical Evidence
Featured Clinical Case:

A 47-year-old man, diagnosed with NBCCS and multiple facial lesions, was treated with HeberFERON in Cuba. After 12 weeks of therapy, the patient showed complete resolution of the lesions without the need for surgical intervention, achieving significant aesthetic and functional improvement.

International recognition:

HeberFERON has been the subject of multiple clinical studies that support its effectiveness. Its success has positioned Cuba as a leader in the management of rare genetic diseases such as NBCCS.

Cuba as a Medical Destination for International Patients

Cuba has become an attractive medical destination for international patients, including those from Latin America and the United States, seeking advanced treatments such as HeberFERON.

Reasons to Choose Cuba:
  • Geographical Proximity: Easy access from Latin American countries.
  • Affordable Cost: Treatments in Cuba are significantly cheaper compared to the United States and Europe.
  • Personalized Care: Patients receive a comprehensive approach that combines medical treatments with psychological support and rehabilitation.
Skin Cancer Prevention and Education

In Latin America, cultural habits and high sun exposure increase the risk of developing skin cancer.

Preventive Strategies:
  1. Sunscreen use: Apply broad-spectrum sunscreen (SPF 30 or higher) regularly, especially in tropical regions.
  2. Skin self-assessment: Regularly examine the skin to identify suspicious lesions.
  3. Public education: Promote awareness campaigns about the risks of sun damage and the importance of early detection.

It is critical to change the cultural perception that sunscreen use is unnecessary, especially in rural communities.

Conclusion: Cuban Leadership in Dermatological Oncology

HeberFERON is an outstanding example of Cuba’s commitment to medical innovation and accessibility. Its effectiveness in treating NBCCS and basal cell carcinoma has significantly improved patients’ quality of life, while reducing complications associated with traditional treatments.

Cuba continues to lead in biotechnology and comprehensive medical care, offering hope to patients around the world and consolidating itself as a global benchmark in dermatological oncology.

References

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top